Diagnostic Imaging Pathways - Phaeochromocytoma

References

1. Sheps SG, Jiang NS, Klee GG. Diagnostic evaluation of phaeochromocytoma. Endocrinology and Metabolic Clin North America 1998;17:397-414. (Review article)
2. Pattou F, Combermale F, Poirette JF, et al. Questionability of the benefits of routine laparotomy as the surgical approach for phaeochromocytomas and abdominal paragangliomas. Surgery 1996;120:1006-12. (Level III evidence)
3. Neumann H, Bausch B, McWhinney S et al Germ-Line Mutations in Non-Syndromic Pheochromocytoma NEJM 2002;346(19) 1459-1466. (Level II Evidence) Click here to view reference
4. Bornstein SR, Stratakis CA, Chrousos GP. Adrenocortical tumors: recent advances in basic concepts and clinical management. Ann Intern Med 1999;130:759-71.
5. Wittles RM, Kaplan EL, Roizen MF. Sensitivity of diagnostic and localization tests for phaeochromocytoma in clinical practice. Arch Intern Med 2000;160:2521-4. (Level IV evidence)
6. Lucon AM, Pereira MA, Mendonca BB, et al. Phaeochromocytoma: study of 50 cases. J Urol 1997;157:1208-12. (Level III evidence)
7. Berglund AS, Hulthen UL, Manhem P, et al. Metaiodobenzylguanidine (MIBG) scintigraphy and computed tomography in clinical practice. Primary and secondary evaluation for localization of phaeochromocytomas. Journal of Internal Medicine 2001;249(3):247-51. (Level II evidence). Click here to view reference
8. Maurea S, Cuocolo A, Reynolds JC, et al. Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med 1993;34:173-9. (Level III evidence)
9. Jalil ND, Pattou FN, Combemale F, et al. Effectiveness and limitations of pre-operative imaging studies for localisation of phaeochromocytomas: a review of 282 cases. Eur J Surg 1998;164:23-8. (Level III evidence)
10. Velchik M, Alavi A, Kressel H, et al. Localization of phaeochromocytoma: MIBG, CT, and MRI correlation. J Nucl Med 1989;30:328-36. (Level III evidence)
11. Shapiro B, Copp JE, Sisson JC, et al. Iodine-131 metaiodobenzylguanidine for the locating of suspected pheochromocytoma: experience in 400 cases. J Nucl Med 1985; 26: 576-85. (Level II/III evidence)
12. Van der Harst E, de Herder WW, Bruining HA, et al. 123I metaiodobenzylguanidine and 111-In octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol & Metabolism 2001;86:685-93. (Level III evidence)
13. Hanson MW, Feldman JM, Beam CA, et al. Iodine 131-labeled metaiodobenzlguanidine scintigraphy and biochemical analyses in suspected phaeochromocytoma. Arch Intern Med 1991;151:1397-1402. (Level II/III evidence)
14. Sawka A, Prebtani A, Thabane L et al. A Stematic review of the literature examining the diagnostic efficacy of measurement of fractionated plasma free metanephrines in the biochemical diagnosis of phaeochromocytoma BMC Endocrine Disorders 2004 4:2 (Level II evidence) Click here to view reference
15. Hoegerle S, Nitzxche E, Altehoefer C et al. Pheochromocytomas: Detection with 18F-DOPA Whole-Body PET - Initial results Radiology 2002; 222:507-12 (Level IV evidence)
16. Hoefnagel C Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours Eur J Nuc Med 1994;21:561-581 (Review Article)
17. Lumachi F, tregnaghi A, Zucchetta P Sensitivity and positive predictive value of CT, MRI and 123I-MIBG scintigraphy in localising pheochromocytomas: A prospective study Nuclear Medicine Communications 2006; 27(7):583-587 (Level II Evidence) Click here to view reference

Further Reading

1. Walther MM, Keiser HR, Linehan WM. Pheochromocytoma: evaluation, diagnosis, and treatment. World J Urol 1999;17:35-9. (Review article)

File Formats

Some documents for download on this website are in a Portable Document Format (PDF). To read these files you might need to download Adobe® Acrobat Reader.